STOCK TITAN
  1. Home
  2. Sec-filings
  3. MANE
  4. [Form 4] Veradermics, Inc Insider Trading Activity

Veradermics insiders receive 300,000 pre-funded warrants

Veradermics, Inc. investment entities reported new derivative awards rather than open-market trades.

Filing Impact
(Very High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Veradermics, Inc. investment entities reported new derivative awards rather than open-market trades. On May 1, 2026, reporting persons including Suvretta Capital Management, LLC and Averill funds reported the indirect acquisition of two blocks of Pre-Funded Warrants for 151,000 and 149,000 underlying shares of Veradermics common stock. These transactions are coded as grants or awards, so they increase indirect exposure to Veradermics without reflecting discretionary buying or selling in the open market.

Insider SUVRETTA CAPITAL MANAGEMENT, LLC, Cowen Aaron, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.
Role Director | Insider | Director | Director
Type Security Shares Price Value
Grant/Award Pre-Funded Warrants 149,000 $99.9999 $14.90M
Grant/Award Pre-Funded Warrants 151,000 $99.9999 $15.10M
Holdings After Transaction: Pre-Funded Warrants — 300,000 contracts (Indirect, See footnotes)
Footnotes (6)
  1. F1. Notes are included on Exhibit 99.1.
  2. F2. Notes are included on Exhibit 99.1.
  3. F3. Notes are included on Exhibit 99.1.
  4. F4. Notes are included on Exhibit 99.1.
  5. F5. Notes are included on Exhibit 99.1.
  6. F6. Notes are included on Exhibit 99.1.
Pre-Funded Warrants granted 151,000 warrants Indirect award on May 1, 2026; 151,000 underlying common shares
Pre-Funded Warrants granted 149,000 warrants Indirect award on May 1, 2026; 149,000 underlying common shares
Total new underlying shares 300,000 shares Sum of underlying common shares for the two warrant awards
Exercise price 0.0000 per share Conversion or exercise price for the Pre-Funded Warrants
Post-transaction holdings (line 1) 151,000 warrants Total Pre-Funded Warrants indirectly owned after first transaction
Post-transaction holdings (line 2) 149,000 warrants Total Pre-Funded Warrants indirectly owned after second transaction
Pre-Funded Warrants financial
"security_title: "Pre-Funded Warrants" with underlying common stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
indirect ownership financial
"ownership_type: "indirect" and ownership_code: "I""
underlying security financial
"underlying_security_title: "Common stock" and underlying_security_shares"
conversion or exercise price financial
"conversion_or_exercise_price: "0.0000""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did MANE reporting persons disclose in this Form 4?
Reporting persons for Veradermics (MANE) disclosed indirect acquisition of Pre-Funded Warrants. Two grants covered 151,000 and 149,000 underlying common shares, increasing their economic exposure through derivative awards rather than open-market stock purchases.

Were the MANE Form 4 transactions open-market buys or option grants?
The MANE Form 4 shows grant or award acquisitions, not open-market buys. Both transactions carry code A and are described as Grant, award, or other acquisition, indicating compensation or deal-related awards of Pre-Funded Warrants.

How many Veradermics shares are underlying the new Pre-Funded Warrants?
The newly reported Pre-Funded Warrants cover a total of 300,000 Veradermics common shares. One line reflects 151,000 underlying shares and the other reflects 149,000, each tied to indirect ownership positions reported in the filing.

Who are the main reporting persons in the Veradermics (MANE) Form 4?
The Form 4 lists Suvretta Capital Management, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen as reporting persons. Several entities are identified as directors of Veradermics through their board representation.

Are the MANE Pre-Funded Warrants held directly or indirectly?
The Pre-Funded Warrants are reported as indirectly owned. Each transaction is marked with ownership type indirect (I) and references footnotes for additional details, indicating the positions are held through related investment entities rather than directly.

Do the MANE Pre-Funded Warrants have an exercise price?
The filing lists a conversion or exercise price of 0.0000 for the Pre-Funded Warrants. That indicates the economic exposure is similar to holding common shares, subject to the full warrant terms described in the company’s detailed documentation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SUVRETTA CAPITAL MANAGEMENT, LLC
(Last)(First)(Middle)
540 MADISON AVENUE
7TH FLOOR
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Pre-Funded Warrants(4)05/01/2026A149,000(2) (5)(6) (5)Common stock149,000(5)$99.9999149,000I(1)See footnotes(1)(2)
Pre-Funded Warrants(4)05/01/2026A151,000(3) (5)(6) (5)Common stock151,000(5)$99.9999151,000I(1)See footnotes(1)(3)
1. Name and Address of Reporting Person*
SUVRETTA CAPITAL MANAGEMENT, LLC
(Last)(First)(Middle)
540 MADISON AVENUE
7TH FLOOR
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Cowen Aaron
(Last)(First)(Middle)
C/O SUVRETTA CAPITAL MANAGEMENT, LLC
540 MADISON AVENUE, 7TH FLOOR
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
Director10% Owner
Officer (give title below)XOther (specify below)
See footnotes
1. Name and Address of Reporting Person*
Averill Master Fund, Ltd.
(Last)(First)(Middle)
C/O SUVRETTA CAPITAL MANAGEMENT, LLC
540 MADISON AVENUE, 7TH FLOOR
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Averill Madison Master Fund, Ltd.
(Last)(First)(Middle)
C/O SUVRETTA CAPITAL MANAGEMENT, LLC
540 MADISON AVENUE, 7TH FLOOR
(Street)
NEW YORK NEW YORK 10022
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Notes are included on Exhibit 99.1.
2. Notes are included on Exhibit 99.1.
3. Notes are included on Exhibit 99.1.
4. Notes are included on Exhibit 99.1.
5. Notes are included on Exhibit 99.1.
6. Notes are included on Exhibit 99.1.
Remarks:
Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature
Suvretta Capital Management, LLC; By: /s/ Andrew Nathanson, General Counsel & Chief Compliance Officer05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on MANE

All MANE news

Trending in the feed

CRBU
Caribou Biosciences to Evaluate Strategic Alternatives Open the live feed